{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:40:49Z","timestamp":1793014849048,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["Veni-09150162010108 and BIRD-NL-10510032120005"],"award-info":[{"award-number":["Veni-09150162010108 and BIRD-NL-10510032120005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["#10510032120003"],"award-info":[{"award-number":["#10510032120003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["CVON2018-28"],"award-info":[{"award-number":["CVON2018-28"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARF-22-924982"],"award-info":[{"award-number":["AARF-22-924982"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Treatment with anti-amyloid-\u03b2 monoclonal antibodies slowed cognitive decline in recent RCTs in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer\u2019s disease (AD). However, stringent trial eligibility criteria may affect generalisability to clinical practice. We extracted eligibility criteria for trials of aducanumab, lecanemab and donanemab, and applied these to participants with MCI and early clinical AD dementia from the population-based Rotterdam Study. Participants underwent questionnaires, genotyping, brain-MRI, cognitive testing, and cardiovascular assessment. We determined amyloid status using a validated prediction model based on age and <jats:italic>APOE-g<\/jats:italic>enotype. Of 968 participants (mean age: 75 years, 56% women), 779 had MCI and 189 dementia. Across trials, around 40% of participants would be ineligible because of predicted amyloid negativity. At least one clinical exclusion criterion was present in 76.3% of participants for aducanumab, 75.8% for lecanemab, and 59.8% for donanemab. Common criteria were cardiovascular disease (35.2%), anticoagulant (31.2%), psychotropic or immunological medication use (20.4%), anxiety or depression (15.9%), or lack of social support (15.6%). One-third were ineligible based on brain-MRI findings alone, similar across trials and predominantly due to cerebral small-vessel disease. Combining amyloid, clinical, and imaging criteria, eligibility ranged from 9% (95% CI:7.0-11.1) for aducanumab, 8% (6.2\u20139.9) lecanemab to 15% (12.4\u201317.5) for donanemab. Findings from recent RCTs reporting protective effects of monoclonal antibodies against amyloid-\u03b2 are applicable to less than 15% of community-dwelling individuals with MCI or early AD. These findings underline that evidence for drug efficacy and safety is lacking for the vast majority of patients with MCI\/AD in routine clinical practice.<\/jats:p>","DOI":"10.1007\/s10654-025-01220-1","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T19:28:47Z","timestamp":1742758127000},"page":"327-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer\u2019s disease to individuals with mild cognitive impairment or early Alzheimer\u2019s disease in the general population"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-7064","authenticated-orcid":false,"given":"Jacqueline J.","family":"Claus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"vom Hofe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekee","family":"van Ijlzinga Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvan","family":"Licher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Neitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike W.","family":"Vernooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"1220_CR1","unstructured":"Gauthier SR-NP, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the Diagnosis of Dementia 2021."},{"issue":"2","key":"1220_CR2","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"1220_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"1220_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"key":"1220_CR6","unstructured":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug. United States Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Accessed 02\u201328 2024."},{"key":"1220_CR7","unstructured":"FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. United States Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 10\u2013\u200904 2024."},{"key":"1220_CR8","unstructured":"US E. LEQEMBI\u00ae Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in Japan 2023. https:\/\/us.eisai.com\/press-releases\/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan#:~:text=%E2%80%9CToday%20LEQEMBI%20received%20approval%2C%20making,of%20the%20disease%20in%20Japan. Accessed 10\u2013\u200909 2023."},{"key":"1220_CR9","unstructured":"Wall JK. Results from Lilly\u2019s Landmark Phase 3 Trial of Donanemab Presented at Alzheimer\u2019s Association Conference and Published in JAMA. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/results-lillys-landmark-phase-3-trial-donanemab-presented. Accessed 02\u201328 2024."},{"key":"1220_CR10","unstructured":"Press release European Medicines Agency accepts Marketing. Authorization Application for lecanemab as treatment for early Alzheimer\u2019s disease. BIOARCTIC. https:\/\/www.bioarctic.se\/en\/wp-content\/uploads\/sites\/2\/2023\/01\/bioarctic-european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-t-230126.pdf. Accessed 02\u201328 2024."},{"issue":"9453","key":"1220_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet. 2005;365(9453):82\u201393.","journal-title":"Lancet"},{"issue":"1","key":"1220_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.25380","volume":"85","author":"PA Boyle","year":"2019","unstructured":"Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer\u2019s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114\u201324.","journal-title":"Ann Neurol"},{"key":"1220_CR13","doi-asserted-by":"crossref","unstructured":"Togher Z, Dolphin H, Russell C, Ryan M, Kennelly SP, O\u2019Dowd S. Potential eligibility for aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria. Int J Geriatr Psychiatry. 2022;37(8).","DOI":"10.1002\/gps.5789"},{"issue":"2","key":"1220_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jgs.17530","volume":"70","author":"A Padovani","year":"2022","unstructured":"Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G. Real-world eligibility for aducanumab depends on clinical setting and patients\u2019 journey. J Am Geriatr Soc. 2022;70(2):626\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1220_CR15","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1111\/jgs.17390","volume":"69","author":"M Canevelli","year":"2021","unstructured":"Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M. Real world eligibility for aducanumab. J Am Geriatr Soc. 2021;69(10):2995\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"16","key":"1220_CR16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2021.15286","volume":"326","author":"TS Anderson","year":"2021","unstructured":"Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for alzheimer disease compared with medicare beneficiaries with alzheimer disease and mild cognitive impairment. JAMA. 2021;326(16):1627\u20139.","journal-title":"JAMA"},{"key":"1220_CR17","doi-asserted-by":"crossref","unstructured":"Pittock RR, Aakre J, Castillo AM et al. Eligibility for Anti-Amyloid treatment in a Population-Based study of cognitive aging. Neurology. 2023;101(19):e1837\u2013e1849.","DOI":"10.1212\/WNL.0000000000207770"},{"issue":"5","key":"1220_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","volume":"35","author":"MA Ikram","year":"2020","unstructured":"Ikram MA, Brusselle G, Ghanbari M, et al. Objectives, design and main findings until 2020 from the Rotterdam study. Eur J Epidemiol. 2020;35(5):483\u2013517. https:\/\/doi.org\/10.1007\/s10654-020-00640-5.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"1220_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/archneur.62.7.1160","volume":"62","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62(7):1160\u20133. discussion 7.","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"1220_CR20","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.3233\/JAD-132558","volume":"42","author":"RF de Bruijn","year":"2014","unstructured":"de Bruijn RF, Akoudad S, Cremers LG, et al. Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam study. J Alzheimers Dis. 2014;42(Suppl 3):S239\u201349.","journal-title":"J Alzheimers Dis"},{"issue":"5 Suppl","key":"1220_CR21","first-page":"S104","volume":"8","author":"D Bos","year":"2012","unstructured":"Bos D, Vernooij MW, Elias-Smale SE, et al. Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging. Alzheimers Dement. 2012;8(5 Suppl):S104\u201311.","journal-title":"Alzheimers Dement"},{"issue":"Pt 9","key":"1220_CR22","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/brain\/awh553","volume":"128","author":"ND Prins","year":"2005","unstructured":"Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(Pt 9):2034\u201341.","journal-title":"Brain"},{"issue":"1","key":"1220_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.neuroimage.2007.05.018","volume":"37","author":"HA Vrooman","year":"2007","unstructured":"Vrooman HA, Cocosco CA, van der Lijn F, et al. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. NeuroImage. 2007;37(1):71\u201381.","journal-title":"NeuroImage"},{"issue":"4","key":"1220_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.neuroimage.2009.01.011","volume":"45","author":"R de Boer","year":"2009","unstructured":"de Boer R, Vrooman HA, van der Lijn F, et al. White matter lesion extension to automatic brain tissue segmentation on MRI. NeuroImage. 2009;45(4):1151\u201361.","journal-title":"NeuroImage"},{"issue":"4","key":"1220_CR25","doi-asserted-by":"publisher","first-page":"106333","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106333","volume":"31","author":"A Andere","year":"2022","unstructured":"Andere A, Jindal G, Molino J, et al. Volumetric white matter hyperintensity ranges correspond to Fazekas scores on brain MRI. J Stroke Cerebrovasc Dis. 2022;31(4):106333.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9","key":"1220_CR26","doi-asserted-by":"publisher","first-page":"e0274562","DOI":"10.1371\/journal.pone.0274562","volume":"17","author":"L Joo","year":"2022","unstructured":"Joo L, Shim WH, Suh CH, et al. Diagnostic performance of deep learning-based automatic white matter hyperintensity segmentation for classification of the Fazekas scale and differentiation of subcortical vascular dementia. PLoS ONE. 2022;17(9):e0274562.","journal-title":"PLoS ONE"},{"issue":"8","key":"1220_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338.","journal-title":"Lancet Neurol"},{"key":"1220_CR28","doi-asserted-by":"crossref","unstructured":"Nguyen Ho PT, van Arendonk J, Steketee RME et al. Predicting amyloid-beta pathology in the general population. Alzheimers Dement. 2023;19(12):5506\u201317.","DOI":"10.1002\/alz.13161"},{"issue":"7624","key":"1220_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"7","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/brain\/awab092","volume":"144","author":"PA Boyle","year":"2021","unstructured":"Boyle PA, Wang T, Yu L, et al. To what degree is late life cognitive decline driven by age-related neuropathologies? Brain. 2021;144(7):2166\u201375.","journal-title":"Brain"},{"key":"1220_CR31","unstructured":"Highlights of prescribing information Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/Drugsatfda_docs\/Label\/2023\/761269Orig1s001lbl.Pdf. Accessed 02\u201325 2025."},{"key":"1220_CR32","unstructured":"Marwan Sabbagh CHD, Honig LS, Cummings JL, Gee M, Kanekiyo M, Dhadd S, Irizarry M, Krame LD, LECANEMAB PHASE 3 CLARITY AD TRIAL: ARIA WITH THE USE OF ANTIPLATELETS OR ANTICOAGULANTS in EARLY ALZHEIMER\u2019S DISEASE. 2023. https:\/\/www.bioarctic.se\/sv\/wp-content\/uploads\/sites\/4\/2023\/04\/ARIA-and-Anticoagulation-Antiplatelet-ADPD2023.pdf Accessed 02\u201328 2024."},{"issue":"5","key":"1220_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B, et al. Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388(5):478\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1220_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"1220_CR35","unstructured":"FDA. Highlights of prescribing information LEQEMBI\u00ae. FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf. Accessed 2023-12-27 2023."},{"issue":"9","key":"1220_CR36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","volume":"22","author":"CRS Belder","year":"2023","unstructured":"Belder CRS, Schott JM, Fox NC. Preparing for disease-modifying therapies in Alzheimer\u2019s disease. Lancet Neurol. 2023;22(9):782\u20133.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1220_CR37","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/alz.12847","volume":"19","author":"E van den Berg","year":"2023","unstructured":"van den Berg E, Vernooij MW, Mattace-Raso FUS, Wolters FJ. Sharpening the tools for the assessment of vascular cognitive impairment. Alzheimers Dement. 2023;19(4):1587\u20138.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1220_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.26819","volume":"95","author":"JD Grill","year":"2024","unstructured":"Grill JD, Flournoy C, Dhadda S, et al. Eligibility rates among Racially and ethnically diverse US participants in phase 2 and phase 3 Placebo-Controlled, Double-Blind, randomized trials of Lecanemab and elenbecestat in early alzheimer disease. Ann Neurol. 2024;95(2):288\u201398.","journal-title":"Ann Neurol"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-025-01220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-025-01220-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-025-01220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:24:43Z","timestamp":1749014683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-025-01220-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s10654-025-01220-1","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Population Screening Act: Rotterdam Study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent to participate in the study and to obtain information from their treating physicians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}